{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=amino+acids&page=6", "query": { "intervention": "amino acids", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 15928, "total_pages": 1593, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=amino+acids&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=amino+acids&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T16:54:50.473Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06005597", "title": "Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dyslipidemias", "Hypercholesterolemia", "Familial Hypercholesterolemia", "ASCVD", "High Cholesterol" ], "interventions": [ { "name": "Combination Therapy", "type": "COMBINATION_PRODUCT" }, { "name": "Monotherapy obicetrapib", "type": "DRUG" }, { "name": "Monotherapy ezetimibe", "type": "DRUG" }, { "name": "Combination Therapy placebo", "type": "OTHER" }, { "name": "Obicetrapib Placebo", "type": "OTHER" }, { "name": "Ezetimibe Placebo", "type": "OTHER" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG", "OTHER" ], "sponsor": "NewAmsterdam Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 407, "start_date": "2024-03-01", "completion_date": "2024-10-16", "has_results": true, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-10-06T16:54:50.473Z", "location_count": 45, "location_summary": "Gilbert, Arizona • Jacksonville, Florida • Port Orange, Florida + 37 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Port Orange", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06005597" }, { "nct_id": "NCT03435250", "title": "Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Lymphoma" ], "interventions": [ { "name": "AG-270", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2018-03-04", "completion_date": "2023-04-20", "has_results": false, "last_update_posted_date": "2024-07-25", "last_synced_at": "2026-10-06T16:54:50.473Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03435250" }, { "nct_id": "NCT03364218", "title": "Nebulized N-Acetyl Cysteine for Bronchiolitis in Inpatient Hospital Use", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Bronchiolitis Acute" ], "interventions": [ { "name": "N-Acetyl Cysteine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Carilion Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Week", "maximum_age": "2 Years", "sex": "ALL", "summary": "1 Week to 2 Years" }, "enrollment_count": 106, "start_date": "2018-02-01", "completion_date": "2020-05-31", "has_results": false, "last_update_posted_date": "2019-09-26", "last_synced_at": "2026-10-06T16:54:50.473Z", "location_count": 1, "location_summary": "Roanoke, Virginia", "locations": [ { "city": "Roanoke", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03364218" }, { "nct_id": "NCT00074490", "title": "Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Leukemia", "Myeloproliferative Disorders", "Multiple Myleoma", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Peripheral blood stem cell (PBSC) transplantation", "type": "PROCEDURE" }, { "name": "T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells", "type": "GENETIC" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Allogeneic hematopoietic stem cell transplant (HSCT)", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "T-Rapa cell Donor Lymphocyte Infusion (DLI)", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "PROCEDURE", "GENETIC" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "11 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "11 Years to 90 Years" }, "enrollment_count": 442, "start_date": "2004-01-01", "completion_date": "2017-08-16", "has_results": true, "last_update_posted_date": "2018-12-31", "last_synced_at": "2026-10-06T16:54:50.473Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Hackensack, New Jersey", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00074490" }, { "nct_id": "NCT01149850", "title": "Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Giant Cell Glioblastoma", "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "microarray analysis", "type": "GENETIC" }, { "name": "DNA methylation analysis", "type": "GENETIC" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "GENETIC" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 50, "start_date": "2010-04-28", "completion_date": "2023-12-08", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-06T16:54:50.473Z", "location_count": 3, "location_summary": "Los Angeles, California • San Diego, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01149850" }, { "nct_id": "NCT02296918", "title": "Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Prolymphocytic Leukemia" ], "interventions": [ { "name": "acalabrutinib", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2014-12-22", "completion_date": "2025-10-22", "has_results": false, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-10-06T16:54:50.473Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02296918" }, { "nct_id": "NCT02209597", "title": "Clinical Study of Generic and Brand Bupropion in Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Bupropion XL 300", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 74, "start_date": "2014-06-25", "completion_date": "2016-08-14", "has_results": true, "last_update_posted_date": "2020-04-24", "last_synced_at": "2026-10-06T16:54:50.473Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02209597" }, { "nct_id": "NCT05153408", "title": "(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Neoplasm", "Carcinoma, Non-Small-Cell Lung", "Respiratory Tract Neoplasms", "Neoplasms", "Neoplasms by Site", "Lung Diseases", "Respiratory Tract Diseases", "Carcinoma, Bronchogenic", "Bronchial Neoplasms", "Adenocarcinoma", "Carcinoma", "Neoplasms by Histologic Type", "Neoplasms, Nerve Tissue", "EGFR C797S", "EGFR C797A", "EGFR L858R", "EGFR Exon 19 Deletion", "EGFR Gene Mutation", "EGF-R Positive Non-Small Cell Lung Cancer", "EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance", "EGFR Activating Mutation", "Thoracic Neoplasms", "Antineoplastic Agents", "Protein Kinase Inhibitors", "EGFR C797G", "EGFR C797X", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "BLU-701", "type": "DRUG" }, { "name": "osimertinib", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Blueprint Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-01-13", "completion_date": "2022-12-09", "has_results": false, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-10-06T16:54:50.473Z", "location_count": 7, "location_summary": "Boston, Massachusetts • Detroit, Michigan • New York, New York + 3 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05153408" }, { "nct_id": "NCT01598025", "title": "Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Leukemia", "Chronic Leukemia", "Myelodysplastic Syndrome", "Non-Hodgkins Lymphoma" ], "interventions": [ { "name": "total-body irradiation (TBI)", "type": "RADIATION" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "19 Years", "sex": "ALL", "summary": "Up to 19 Years" }, "enrollment_count": 3, "start_date": "2012-05-02", "completion_date": "2017-10-16", "has_results": true, "last_update_posted_date": "2018-08-09", "last_synced_at": "2026-10-06T16:54:50.473Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01598025" }, { "nct_id": "NCT00805935", "title": "Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Polycystic Ovarian Syndrome", "Infertility" ], "interventions": [ { "name": "Menotropin", "type": "DRUG" }, { "name": "Progesterone vaginal insert", "type": "DRUG" }, { "name": "Follitropin beta", "type": "DRUG" }, { "name": "Progesterone in oil", "type": "DRUG" }, { "name": "leuprolide acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ferring Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "42 Years", "sex": "FEMALE", "summary": "18 Years to 42 Years · Female only" }, "enrollment_count": 110, "start_date": "2009-01", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2012-01-27", "last_synced_at": "2026-10-06T16:54:50.473Z", "location_count": 6, "location_summary": "Littleton, Colorado • Clearwater, Florida • Chicago, Illinois + 3 more", "locations": [ { "city": "Littleton", "state": "Colorado" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT00805935" } ] }